Metabolic & GLP-1

1. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   Semaglutide's weight effect holds up in Asian adults, pooled trials find

   In a meta-analysis of five randomised trials in 2614 Asian adults with overweight or obesity, once-weekly semaglutide 2.4 mg reduced body weight by 8.20% more than placebo, with smaller waist circumference, BMI and systolic blood pressure alongside mostly mild gastrointestinal side effects.

   ⚠What it shows: Pooled data from five placebo-controlled RCTs (2614 Asian adults with overweight or obesity), all rated low risk of bias, but heterogeneity was high for weight, waist and BMI (I2 = 84%, 84% and 66%) and long-term and real-world outcomes were not assessed.Meta-analysis · Diabetes Obes Metab

   Full breakdown →Visceral fat explained →Calorie Deficit Calculator →Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials. Diabetes Obes Metab 2025
2. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   Tirzepatide trims 16.32% of body weight in people without diabetes

   In a meta-analysis of six randomised trials in adults with overweight or obesity but without diabetes, tirzepatide cut body weight by 16.32% versus placebo, but roughly tripled the risk of nausea, diarrhoea and constipation, and more than doubled discontinuation due to adverse events.

   ⚠What it shows: Meta-analysis of six placebo-controlled RCTs in adults with overweight or obesity without diabetes; gastrointestinal side effects, serious GI events and drop-out due to adverse effects were all significantly higher than placebo.Meta-analysis · Obes Rev

   Full breakdown →Energy balance explained →Calorie Deficit Calculator →Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Obes Rev 2025
3. Metabolic & GLP-1preliminary · human dataAdded 8 August 2026

   Pilates lowered long-term blood sugar markers in type 2 diabetes

   A meta-analysis of randomised trials found Pilates lowered HbA1c by 0.96% and fasting blood sugar by 23.98 mg/dL in people with type 2 diabetes compared with standard care.

   ⚠What it shows: Meta-analysis of seven RCTs with small pooled samples (n=275 for HbA1c, n=231 for fasting glucose); Pilates formats varied across trials and larger studies are needed.Review · J Korean Biol Nurs Sci

   Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Effects of Pilates exercise on glycated hemoglobin and fasting blood sugar in type 2 diabetes: a systematic review and meta-analysis. J Korean Biol Nurs Sci 2025
4. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   One workout keeps your fat burning into tomorrow

   A single endurance workout keeps resting fat oxidation elevated on the day of exercise and into the following day, a meta-analysis finds. Total energy expended in the session and the exerciser's aerobic fitness, not exercise intensity, predicted the size of the effect.

   ⚠What it shows: Meta-analysis pooling varied exercise-study protocols; the abstract does not detail individual sample sizes; the sex difference appeared only in the fasted (postabsorptive) state; measures fat oxidation, not fat loss.Meta-analysis · J Appl Physiol (1985)

   Full breakdown →VO2max Calculator →Determinants of resting lipid oxidation in response to a prior bout of endurance exercise. J Appl Physiol (1985) 2014
5. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   Exercise cut fasting insulin across 58 trials in women

   Pooling 58 randomised trials in adult women, exercise interventions reduced fasting insulin, insulin resistance (HOMA-IR) and fasting glucose compared with control. IGF-1 rose, with no clear effect on IGFBP-3 or the IGF-1:IGFBP-3 ratio, and the evidence was graded strong only for fasting insulin and insulin resistance.

   ⚠What it shows: Systematic review and meta-analysis of 58 randomised controlled trials in adult women; no observational or Mendelian randomisation studies qualified, evidence certainty was strong for only two of the outcomes, and effects on C-peptide and HbA1c remain unexamined.Systematic review · Cancer Epidemiol Biomarkers Prev

   Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Linking Physical Activity to Breast Cancer Risk via Insulin/Insulin-Like Growth Factor Signaling System, Part 1: The Effect of Physical Activity on the Insulin/Insulin-Like Growth Factor Signaling System. Cancer Epidemiol Biomarkers Prev 2022
6. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   GLP-1 in a pill: big weight loss, familiar gut toll

   A meta-analysis of ten randomised trials found oral small-molecule GLP-1 receptor agonists significantly reduced body weight, waist circumference and HbA1c in adults with type 2 diabetes or obesity, and made a weight loss of 15% or more 10.61 times more likely. Gastrointestinal side effects rose sharply, but serious adverse events did not increase.

   ⚠What it shows: Meta-analysis of ten RCTs in adults with type 2 diabetes or obesity; the abstract does not report total participant numbers or trial durations, and gastrointestinal side effects were substantially more common on the drugs.Meta-analysis · Front Endocrinol (Lausanne)

   Full breakdown →Insulin sensitivity explained →Calorie Deficit Calculator →Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2026
7. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   Tirzepatide improves how physically capable people feel

   A meta-analysis of six randomised trials in 4531 adults with overweight or obesity found once-weekly tirzepatide (10 or 15 mg) improved patient-reported physical function versus placebo, by 2.26 points on the SF-36 physical function domain and 10.10 points on the IWQOL-Lite-CT physical function subscale, though between-study heterogeneity was extreme.

   ⚠What it shows: Meta-analysis of six RCTs (4531 participants, 2802 on tirzepatide); outcomes were self-reported questionnaires, heterogeneity was extreme (I2 = 99.8%) and GRADE certainty only moderate due to risk of bias and inconsistency.Meta-analysis · Diabetes Obes Metab

   Full breakdown →Healthspan explained →Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis. Diabetes Obes Metab 2026
8. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   Weight loss on tirzepatide roughly doubles without diabetes

   In a meta-analysis of ten randomised trials, once-weekly tirzepatide reduced body weight by an average of 18.11 kg versus placebo in adults without diabetes, but by 9.06 kg in adults with diabetes, with mostly mild-to-moderate side effects in both groups.

   ⚠What it shows: Meta-analysis of placebo-controlled RCTs of at least 26 weeks: five trials (n=2,174) in adults with diabetes and five (n=4,467) without. The abstract does not explain why the effect differs by diabetes status.Meta-analysis · Int J Obes (Lond)

   Full breakdown →Energy balance explained →Calorie Deficit Calculator →Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis. Int J Obes (Lond) 2025
9. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   Semaglutide cuts heart-rhythm and cardiovascular risks in type 2 diabetes

   A meta-analysis of 30 randomised trials in 32490 people with type 2 diabetes found semaglutide reduced atrial fibrillation, complete heart block, death from cardiovascular causes and revascularisation compared with controls, with longer treatment showing greater benefits for heart-rhythm outcomes.

   ⚠What it shows: Meta-analysis of 30 RCTs in people with type 2 diabetes only; confidence intervals for atrial fibrillation and cardiovascular death approach the line of no effect, and the findings may not extend to people without diabetes.Meta-analysis · Front Endocrinol (Lausanne)

   Full breakdown →Heart Age Calculator →Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2025
10. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Night-shift fasting hints at better post-meal glucose

    A systematic review found only four randomised trials of meal-timing changes in shift workers: nearly 11 hours of overnight fasting was linked to lower post-meal glucose and non-esterified fatty acid responses versus eating and snacking at night, while insulin resistance improved in just one trial and HDL-C changed in none.

    ⚠What it shows: Systematic review of only four RCTs in adult shift workers, with different fasting windows and short durations; the authors explicitly question the robustness and generalisability of these preliminary positive signals.Review · Nutr Health

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Cardiometabolic status among shift workers under meal time regulation: A systematic review of randomized controlled trials. Nutr Health 2026
11. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    GLP-1 drugs shaved a few mmHg off blood pressure

    Pooling 30 randomised controlled trials with 37 072 overweight or obese patients, GLP-1 receptor agonists lowered systolic blood pressure by 3.37 mmHg and diastolic by 1.05 mmHg compared with placebo. The effect was consistent across diabetes status, drug formulation, follow-up duration and route of administration, with the exception of exenatide subgroups.

    ⚠What it shows: Meta-analysis of 30 RCTs in 37 072 overweight or obese patients, but blood pressure was a secondary outcome in most of them and the absolute reductions are modest; these are prescription medicines whose use and monitoring sit with a clinician.Meta-analysis · J Hypertens

    Full breakdown →Metabolic syndrome explained →Heart Age Calculator →Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials. J Hypertens 2025
12. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    GLP-1 lipid drop wasn't explained by weight loss

    A meta-analysis of placebo-controlled randomised trials found GLP-1 receptor agonists modestly reduced LDL cholesterol (mean difference -2.93 mg/dL) and cut total cholesterol by about 7 mg/dL, while triglycerides, VLDL-C and HDL-C did not change significantly. Meta-regression found weight change did not explain the LDL or total cholesterol reductions.

    ⚠What it shows: Meta-analysis of placebo-controlled RCTs with extremely high heterogeneity (I2 above 99% in the meta-regressions); the absolute lipid changes are small, most trials were not designed with lipids as the primary endpoint, and these are prescription medicines managed clinically.Meta-analysis · Curr Med Res Opin

    Full breakdown →ApoB explained →Heart Age Calculator →Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials. Curr Med Res Opin 2025
13. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    Lifting weights improves blood sugar in type 2 diabetes

    An umbrella review of 43 systematic reviews found resistance training in adults with type 2 diabetes was associated with HbA1c reductions of roughly 0.3-0.6 percentage points, systolic blood pressure drops of about 4-7 mmHg, small lipid improvements and large gains in muscle strength.

    ⚠What it shows: Umbrella review of 43 reviews with moderate GRADE certainty for key outcomes, but substantial heterogeneity, heavy overlap of primary trials across reviews, and frequent methodological flaws in the included syntheses.Systematic review · Metabolism

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Resistance training and diabetes mellitus type 2: An umbrella review of systematic reviews and meta-analyses on glycemic and cardiometabolic outcomes. Metabolism 2026
14. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Breaking up sitting trimmed post-meal glucose

    In a meta-analysis of eight acute randomised crossover trials in 159 sedentary adults at metabolic risk, brief 'exercise snacks' that interrupt sitting reduced post-meal glucose iAUC by 5.69 mmol·h/L versus uninterrupted sitting. Heterogeneity was high (I² = 85%), the prediction interval crossed zero, and the insulin reduction was not statistically significant.

    ⚠What it shows: Only eight acute laboratory crossover trials, 159 sedentary adults at metabolic risk, with the glucose result resting on five trials; heterogeneity was very high, the prediction interval crossed the null, and no long-term outcomes were measured.Meta-analysis · Front Endocrinol (Lausanne)

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Acute effects of "exercise snacks" on postprandial glucose and insulin responses in populations at metabolic risk: a meta-analysis with exploratory meta-regression and vascular outcomes. Front Endocrinol (Lausanne) 2026
15. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Stronger semaglutide dose, only a modest extra gain

    A network meta-analysis of 24 phase 3 trials lasting at least 52 weeks found liraglutide, semaglutide and tirzepatide all reduced body weight, waist circumference and BMI versus placebo, with tirzepatide 15 mg ranked highest and liraglutide 3.0 mg producing the smallest weight loss. Semaglutide 7.2 mg ranked above semaglutide 2.4 mg on every efficacy endpoint, but the average incremental benefit was around 2-3 percentage points.

    ⚠What it shows: Network meta-analysis of 24 phase 3 RCTs in adults with BMI of 25 or above; most comparisons between doses are indirect rather than head-to-head, heterogeneity for efficacy outcomes was considerable, and few between-dose differences reached statistical significance. Says nothing about people outside these trial populations.Study · J Endocrinol Invest

    Full breakdown →Calorie Deficit Calculator →Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis. J Endocrinol Invest 2026
16. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    Heavy lifting topped the table for HbA1c

    A network meta-analysis of 29 randomised trials in 1,301 middle-aged and older adults with type 2 diabetes found high-intensity resistance training produced the largest HbA1c reduction versus usual care (MD -0.62), ranking top of 10 exercise interventions, while moderate-intensity resistance training led on fasting glucose and high-intensity aerobic training drove the biggest gains in peak oxygen uptake. No intervention significantly reduced resting heart rate.

    ⚠What it shows: Network meta-analysis of 29 RCTs and 1,301 participants with type 2 diabetes; only the HbA1c result for high-intensity resistance training reached moderate certainty, the fasting glucose and blood pressure networks were rated low or very low, and the VO2peak network was sparse and described as exploratory.Meta-analysis · Front Public Health

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Comparative effects of different intensities of aerobic and resistance exercise on glycemic control and cardiorespiratory fitness in middle-aged older patients with type 2 diabetes: a network meta-analysis. Front Public Health 2026
17. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    Adding weights beat cardio alone for blood sugar

    Across 16 randomised trials with 1401 participants with type 2 diabetes, exercise significantly lowered HbA1c (SMD -0.46) and fasting blood glucose (SMD -0.52), with combined aerobic plus resistance training (SMD -0.71) beating aerobic exercise alone (SMD -0.32); the insulin resistance index did not improve significantly.

    ⚠What it shows: Meta-analysis of 16 randomised trials totalling 1401 people with type 2 diabetes; trial quality was assessed with the Cochrane risk-of-bias tool but individual protocols, durations and medication use varied, the BMI reduction only reached significance after removing an outlier study, and the insulin resistance index showed no significant change.Meta-analysis · Front Endocrinol (Lausanne)

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Meta-analysis of the effects of exercise intervention on glucose metabolism and body composition in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2026
18. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Massage added to lifestyle change moved the scales

    Pooling 13 randomised trials in people with simple obesity, adding massage to a lifestyle programme was associated with larger falls in body weight (mean difference -4.85 kg) and BMI (-2.65) than lifestyle change alone, along with reductions in waist circumference, total cholesterol, triglycerides, LDL cholesterol, fasting insulin and HOMA-IR. HDL cholesterol also fell rather than rose.

    ⚠What it shows: Thirteen mostly small randomised trials drawn largely from Chinese-language databases, mixing adults with children and adolescents, and with extreme statistical heterogeneity for the blood-lipid outcomes (I² up to 98.3%); effects this large from adding massage are hard to explain and need independent replication before being taken at face value.Meta-analysis · Medicine (Baltimore)

    Full breakdown →Insulin sensitivity explained →Calorie Deficit Calculator →Comparative effectiveness of massage combined with lifestyle intervention and lifestyle intervention alone for simple obesity: A systematic review and meta-analysis. Medicine (Baltimore) 2025
19. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    GLP-1 drugs linked to lower fracture risk

    Pooling 54 randomised trials in 49,602 people with type 2 diabetes, GLP-1 receptor agonists were associated with a lower risk of bone fracture than placebo or other glucose-lowering drugs, and exenatide ranked as the most favourable agent (RR 0.17, 95% CI 0.03-0.67). A statistically significant inconsistency appeared in some of the indirect comparisons.

    ⚠What it shows: Bayesian network meta-analysis of 54 RCTs (49,602 participants, 28,353 on GLP-1 RAs) in people with type 2 diabetes, not healthy adults. Fractures were rarely the trials' main outcome, the exenatide estimate rests on very few events with a wide confidence interval, and the network showed significant inconsistency in some comparisons, so drug rankings are fragile.Meta-analysis · Osteoporos Int

    Full breakdown →Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int 2018
20. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Bigger weight loss, bigger heart benefit on GLP-1s

    Pooling 8 cardiovascular outcome trials of GLP-1 receptor agonists in type 2 diabetes (60079 patients), the trials that lowered HbA1c and body weight most also showed the largest reductions in major cardiovascular events, at an estimated 25% lower relative risk per 1% absolute HbA1c reduction and 7% per 1 kg of weight lost. Reductions in systolic blood pressure and LDL cholesterol were not associated with event reduction.

    ⚠What it shows: Trial-level meta-regression across 8 cardiovascular outcome trials (60079 patients, 30693 on GLP-1 RAs) in type 2 diabetes. Because it correlates average results between trials rather than tracking individuals, it cannot show that losing weight caused the event reduction, and the weight-loss association was only just statistically significant (p = 0.047).Meta-analysis · Cardiovasc Drugs Ther

    Full breakdown →Heart Age Calculator →Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials. Cardiovasc Drugs Ther 2025
21. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Prebiotics left blood sugar untouched in prediabetes

    Across 11 randomised trials in 546 adults with prediabetes, prebiotic supplementation did not significantly change fasting glucose, insulin, HbA1c, HOMA-IR or blood lipids, and did not shift BMI or waist circumference. The single significant result was a reduction in body fat percentage, rated very low certainty.

    ⚠What it shows: Systematic review and meta-analysis of 11 randomised trials totalling 546 adults with prediabetes; the authors themselves rate certainty in the pooled estimates as very low for most outcomes, and the one positive finding sits on a wide confidence interval.Meta-analysis · J Nutr

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Effect of Prebiotic Supplementation on Health Status in Adults with Prediabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Nutr 2025
22. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    Glucose monitors modestly lower HbA1c in type 2 diabetes

    In a meta-analysis of 4 randomised trials covering 566 adults with type 2 diabetes in primary care, continuous glucose monitoring cut HbA1c by 0.46% at 6-8 months and 0.33% at 12-14 months versus usual care, and improved device satisfaction, but quality of life did not change.

    ⚠What it shows: Meta-analysis of only 4 multisite RCTs (n=566) in primary care settings; CGM types were mixed (real-time, retrospective and intermittently scanned), and quality of life showed no improvement.Meta-analysis · Sci Diabetes Self Manag Care

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Does Continuous Glucose Monitoring Improve Glycemic Control and Quality of Life Among Adults With Type 2 Diabetes in Primary Care Settings? A Systematic Review and Meta-Analysis. Sci Diabetes Self Manag Care 2026
23. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    HIIT trimmed 24-hour glucose more than steady cardio

    In a meta-analysis of 12 interventional studies with 177 adults with type 2 diabetes, high-intensity interval training lowered 24-hour mean glucose, post-meal glucose and time spent in hyperglycaemia compared with no exercise, and outperformed moderate-intensity continuous training on 24-hour mean glucose and hyperglycaemic time. Effects on glycaemic variability (mean amplitude of glycemic excursions) remained uncertain.

    ⚠What it shows: Systematic review and meta-analysis, but only 12 studies and 177 participants in total, all adults with type 2 diabetes; GRADE certainty was rated very low to low because of methodological limitations and heterogeneity between trials.Meta-analysis · Front Endocrinol (Lausanne)

    Full breakdown →HIIT explained →Metabolic Fitness Index →High-intensity interval training and continuous glucose monitoring-derived glycemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2026
24. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Two fasting days a week moved blood pressure and lipids

    Six months of the 5:2 diet was associated with weight loss of -6.3% in overweight or obese adults with type 2 diabetes and -5.0% in those without, alongside improvements in waist circumference, blood pressure, HDL and LDL cholesterol and adiponectin. HDL and adiponectin improvements were still present at the 12-month follow-up in both groups.

    ⚠What it shows: Secondary analysis of a non-randomised six-month controlled trial: 97 recruited, 93 completed and 82 returned at 12 months, and everyone followed the same 5:2 diet with no non-fasting comparison arm, so the changes cannot be separated from weight loss.Clinical trial · Int J Mol Sci

    Full breakdown →Metabolic syndrome explained →Calorie Deficit Calculator →The 5:2 Diet Reduces Risk Factors for Cardiovascular Disease in Subjects with and Without Type 2 Diabetes-A Non-Randomized Controlled Trial. Int J Mol Sci 2026

Back to the full archive · this week’s studies